Page
%P
-
Article
Open AccessTreatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group
Idelalisib in combination with rituximab is an efficacious treatment for patients suffering from chronic lymphocytic leukemia (CLL) with known limitations due to toxicities. However, the benefit after prior B...
-
Article
Open AccessSequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
-
Article
Open AccessThe impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
-
Article
Open AccessClonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Deciphering the evolution of cancer cells under therapeutic pressure is a crucial step to understand the mechanisms that lead to treatment resistance. To this end, we analyzed whole-exome sequencing data of ei...